Table 2 Baseline characteristics of patients claiming > 5 and < 5 bromocriptine prescriptions
Variable | > 5 claimed bromocriptine percriptions (n = 603) | < 5 claimed bromocriptine percriptions(n = 2432) | p-value |
|---|---|---|---|
Age at onset (year) | 35.0 [28.7, 44.5] | 31.3 [27.6, 35.5] | < 0.0001 |
Comorbidities, n (%) | |||
Ischemic heart disease | 7 (1.2) | 13 (0.5) | 0.16 |
Acute myocardial infarction | ≤ 3 (NA) | ≤ 3 (NA) | NA |
Atrial fibrillation | 5 (0.8) | ≤ 3 (NA) | NA |
Ischemic stroke | 7 (1.2) | 8 (0.3) | 0.02 |
Transient ischemic attack | 4 (0.7) | ≤ 3 (NA) | NA |
Embolism | 0 (0.0) | 0 (0.0) | NA |
Pulmonary embolism | 0 (0.0) | 4 (0.2) | 0.71 |
Deep vein thrombosis | ≤ 3 (NA) | 13 (0.5) | NA |
Atherosclerosis | 6 (1.0) | 0 (0.0) | < 0.0001 |
Coagulopathy | ≤ 3 (NA) | 4 (0.2) | NA |
Hypertension | 41 (6.8) | 34 (1.4) | < 0.0001 |
Diabetes | 18 (3.0) | 24 (1.0) | 0.0004 |
Diagnosis of alcohol misuse | 15 (2.5) | 38 (1.6) | 0.17 |
Chronic obstructive lung disease | 8 (1.3) | 13 (0.5) | 0.07 |
Malignancy | 18 (3.0) | 19 (0.8) | < 0.0001 |
Chronic renal disease | 5 (0.8) | 11 (0.5) | 0.41 |
Abnormal liver function | 6 (1.0) | 8 (0.3) | 0.07 |
Medication, n (%) | |||
Beta-blockers | 34 (5.6) | 48 (2.0) | < 0.0001 |
Calcium channel blockers | 19 (3.2) | 19 (0.8) | < 0.0001 |
RAS inhibitors | 20 (3.3) | 18 (0.7) | < 0.0001 |
Vasodilators | 0 (0.0) | 0 (0.0) | NA |
Antiadrenergic drugs | ≤ 3 (NA) | 6 (0.2) | NA |
Thiazides | 45 (7.5) | 39 (1.6) | < 0.0001 |
Loop diuretics | 26 (4.3) | 31 (1.3) | < 0.0001 |
Spironolactone | 7 (1.2) | 4 (0.2) | 0.001 |
Diuretics, combination | 7 (1.2) | 5 (0.2) | 0.003 |
Digoxin | 0 (0.0) | 6 (0.2) | 0.48 |
Statins | 12 (2.0) | 6 (0.2) | < 0.0001 |
Antidiabetics | 22 (3.6) | 33 (1.4) | 0.0003 |
Aspirin | 18 (3.0) | 15 (0.6) | < 0.0001 |
ADP inhibitors | 0 (0.0) | 0 (0.0) | NA |
Anticoagulants | ≤ 3 (NA) | ≤ 3 (NA) | NA |